Context Therapeutics’ (CNTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

A number of other brokerages have also commented on CNTX. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities assumed coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective on the stock. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Wednesday, January 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.17.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX opened at $0.77 on Friday. The firm has a market cap of $57.88 million, a PE ratio of -0.85 and a beta of 2.06. The firm’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.44. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently bought and sold shares of the company. State Street Corp boosted its stake in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of Context Therapeutics during the third quarter worth $3,689,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics during the third quarter worth $89,000. Clear Harbor Asset Management LLC lifted its stake in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the period. Finally, MPM Bioimpact LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $15,441,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.